Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinA new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteersMucosal resident memory CD4 T cells in protection and immunopathologyTuberculosis vaccine types and timingsPrime-boost approaches to tuberculosis vaccine developmentEffects of MVA85A vaccine on tuberculosis challenge in animals: systematic reviewA review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy dataPreclinical evidence for implementing a prime-boost vaccine strategy for tuberculosisSimultaneous immunization against tuberculosisThe TB pandemic: an old problem seeking new solutions.ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs.Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung.MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infectionThe next 10 years for tuberculosis vaccines: do we have the right plans in place?bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs.Latency antigen α-crystallin based vaccination imparts a robust protection against TB by modulating the dynamics of pulmonary cytokinesThe ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.Whole genome response in guinea pigs infected with the high virulence strain Mycobacterium tuberculosis TT372Molecular epidemiology of tuberculosis: current insights.Animal models of tuberculosis: Guinea pigs.Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis.The importance of animal models in tuberculosis vaccine development.Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferonImprove protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.The success and failure of BCG - implications for a novel tuberculosis vaccine.Tuberculosis: from genome to vaccine.Vaccines for tuberculosis: novel concepts and recent progress.Vaccines for bovine tuberculosis: current views and future prospects.Tuberculosis vaccines: current status and future prospects.The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans.Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaquesHeterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.Tuberculosis subunit vaccines: from basic science to clinical testing.Tuberculosis: vaccines in the pipeline.A New Vaccine for Tuberculosis: The Challenges of Development and DeploymentViral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
P2860
Q22242669-948FC396-829A-4F5E-BCAC-1B16987AB0A6Q24657992-07E0444B-255E-4626-B10A-91545CF2C718Q26823137-E1B4678B-A117-4742-81BF-D0EDB139393BQ26862762-3334428E-03BD-4701-9550-D5B11AB4749BQ27024526-B44D0E1A-C2C4-4A46-9700-F612E17CDCC5Q28088745-51526F24-3F4F-4571-BC27-B48A34A9D5B3Q28383049-51CBEA1E-BF1E-4C0F-974C-B38AEAD93A29Q28730427-98D2F0E6-5147-418A-A0A4-F110DC403418Q28742666-E58C52CB-E73F-4389-9EC5-03F80D0884F3Q30360726-206723CC-4436-47BD-9D29-41DE0E22604CQ33330264-9FBC9663-3E7B-4A58-9F02-494F587D7752Q33389187-148C761F-F63A-40FD-A7EA-841247426599Q33430265-3D993D35-58B9-479B-B23A-3F78902325F4Q33466022-879FB809-C23C-40DB-B9DB-D3F0979797FBQ33518452-A93C1C89-D747-4197-B7EF-ACE988E49AD2Q33659150-EB4B91F0-07F4-45C6-9504-944A3E2FDD36Q33848397-89218F81-D59D-438B-9EA0-F518E8DDD63DQ33886491-192EB84E-D319-4729-B1D2-4685AB0285B6Q34260863-6242B630-1C47-4074-87EA-F8F76A6A7F3CQ35042642-A56146D3-F9A0-4BFF-BB74-1EE4A61FAC59Q35070843-CBDAE8D6-5A9D-4F70-BC1A-248D05818354Q35663870-E4243216-50D2-4613-AA28-D4CC128A90C8Q35717942-5A43852F-DA6D-4D45-9925-649ECD534CA9Q35895817-3810E7C5-F908-492E-941A-1548102AB2F9Q35949758-96873033-9723-45FA-AE7D-1B19F4069EAEQ36094423-CE6A4E29-437E-4086-922D-0DDC1E0871B2Q36191944-FE72314C-9DC4-4BA6-A4B6-0B9069BAA68CQ36238724-4E67881A-10D6-47BD-A45B-2D99B972BE00Q36285657-259361FE-2CB4-4A30-BAC0-E455641E928BQ36350586-C0ED76C7-9BDD-4166-AFC4-A5DEE232669AQ36458393-C330508E-0B9F-4DE1-B76F-71FD16AC0242Q36636763-176CD17C-0EA4-48F2-A43A-A26274301881Q36736465-5231C301-D8D8-4D87-A84C-9515B2AE5739Q36826315-27ED0F5E-7331-4EC9-972D-00DEB52A90F5Q36899073-109021CE-77DA-4033-970E-5B19E9671559Q36950010-64620C4B-5103-495B-8B4C-4D89B00A603FQ36960497-71130AA2-CD29-42BA-A755-78D7007C0443Q37194790-528FBDC9-C8FD-4D1C-9516-D9007620B0C7Q37222364-4BC3B70D-C117-4A39-AD4E-C9AE96DD9A85Q37274874-7537A701-8CA6-4B44-A9C9-5E23392AB683
P2860
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Evaluation of vaccines in the ...... fection model of tuberculosis.
@en
type
label
Evaluation of vaccines in the ...... fection model of tuberculosis.
@en
prefLabel
Evaluation of vaccines in the ...... fection model of tuberculosis.
@en
P2093
P50
P1433
P1476
Evaluation of vaccines in the ...... fection model of tuberculosis.
@en
P2093
Adrian Hill
Ann Williams
Debbie Smith
Douglas B Lowrie
Graham A Hall
Graham J Hatch
Karen Blake
Karen E Gooch
Kees L M C Franken
P356
10.1016/J.TUBE.2004.09.009
P50
P577
2005-01-20T00:00:00Z